manuel mª mazo vega

Post on 19-Mar-2016

58 Views

Category:

Documents

4 Downloads

Preview:

Click to see full reader

DESCRIPTION

U n i v e r s i d a d d e N a v a r r a. CENTRO DE INVESTIGACIÓN MÉDICA APLICADA. TRANSPLANTATION OF MESENCHYMAL STEM CELLS EXERTS A GREATER LONG-TERM EFFECT THAN BM-MNC IN CHRONIC MYOCARDIAL INFARCTION IN RAT. MANUEL Mª MAZO VEGA. Cardiovascular diseases: First cause of mortality - PowerPoint PPT Presentation

TRANSCRIPT

TRANSPLANTATION OF MESENCHYMAL STEM CELLS EXERTS A GREATER LONG-TERM EFFECT

THAN BM-MNC IN CHRONIC MYOCARDIAL INFARCTION IN RAT

MANUEL Mª MAZO VEGA

U n i v e r s i d a d d e N a v a r r a

CENTRO DE INVESTIGACIÓN MÉDICA APLICADA

MYOCARDIAL INFARCTION

The world health report 2004, World Health Organization

Cardiovascular diseases:

-First cause of mortality

-Myocardial infarction: 12,6%

CARDIOVASCULAR DISEASES

30%

CANCER+RESP DISEAS +DIABETES

22%

MATERNAL AND PERINATAL COND, NUTRITIONAL STATE

30%

OTHER CHRONIC DISEAS. 9%

INJURIES 9%

Nitrates

Aspirin

ACEi

ARB

Aldosterone antagonists

Estatins

Beta-Blockers

Inflammatory cytokines antagonists

Neutral endopeptidase inhibitors

PHARMACOLOGICAL SURGICAL

Reperfusion

Transplant

REGENERATIVE

Gene Therapy

Cell Therapy

MYOCARDIAL INFARCTION: TREATMENTS

STEM CELL THERAPY

STEM CELL THERAPY

EXPERIMENTAL DESIGN

SPRAGUE-DAWLEY RAT (+Cyclosporin)

GFP+ S-D RAT

BM-MNC GFP+ MSC GFP+

CD73+

CD45- CD90+

CD44+

RT1A+

RT1B-

CD31-

CH

ON

DR

OC

YTE

AD

IPO

CYT

EO

STEO

CYT

EPhenotype Differentiation

Implant (106 cell)

+0 d

Infarct

Eco

microPET

-30 dEco

+30 d+14 d+7 d

Histological Analysis

Eco

microPET

+90 d

5-6 weeks

% L

VEF

MEDIUM BM-MNC MSCPRE-IMPLANT 3 MONTHS

* *

0

10

20

30

40

50

60

RESULTS: CARDIAC FUNCTION

% 18

F-FD

G U

PTA

KE

(ALL

SEG

MEN

TS)

% 18

F-FD

G U

PTA

KE

(INF.

SEG

MEN

TS)

MEDIUM BM-MNC MSC

MEDIUM BM-MNC MSC

A**

*B

C

MED

IUM

MSC

BM

-MN

C

PRE-IMPL 3 MONTHS

60

65

70

75

80

85

35

40

45

50

55

60

RESULTS: TISSUE METABOLISM

A B D

E F H

I J L

1 WEEK 2 WEEKS 3 MONTHSM

EDIU

MB

M-M

NC

MSC

C

G

K

1 MONTH

RESULTS: ENGRAFTMENT

RESULTS: INFLAMMATION

0

500

1000

1500

2000

2500

INFA

RC

T

CD

68+/

mm

2

A CB DPE

RI-I

NFA

RC

T C

D68

+/m

m2

1 WEEK 2 WEEKS 1 MONTH

E GF

MEDIUM BM-MNC MSC

H

TOPRO3 GFP CD68 MERGEDLK MJI MERGED

MEDIUM

BM-MNC

MSC

1 WEEK 2 WEEKS 1 MONTH

MEDIUM

BM-MNC

MSC

**

**

** ****

**

0

100

200

300

400CD68 TOPRO3 CD68 TOPRO3

GFP CD68 TOPRO3 GFP CD68 TOPRO3

CD68 TOPRO3

GFP CD68 TOPRO3

MEDIUM BM-MNC MSC

A B

* *

*

RESULTS: INFLAMMATION

50

55

60

65

70

75

% IN

FAR

CTE

D L

V

*

MEDIUM BM-MNC MSC

KJ

MEDIUM BM-MNC MSC

LI

% C

VF *

MEDIUM BM-MNC MSC

ON

MEDIUM BM-MNC MSC

PM

0

5

10

15

20

25

% S

M-P

OSI

TIVE

AR

EA

0

300

600

900

1200

00,5

11,5

22,5

3G

B

MEDIUM BM-MNC

C

MSC

D

MEDIUM BM-MNC MSC

*

****

**

MEDIUM BM-MNC MSC

A

F

MEDIUM BM-MNC MSC

HE

CAV1 DAPI CAV1 DAPI CAV1 DAPI

αSMA DAPI αSMA DAPI αSMA DAPI

CA

PILL

AR

IES/

mm

2

RESULTS: MECHANISMS OF ACTION

01020304050

01020304050

0

50

100

150

050

100150200

0

50100150200

0

50

100

150

####

PCN

A+C

AV1

+/m

m2

1 WEEK 2 WEEKS

**** ****

****

*

****

#

****

1 WEEK 2 WEEKS

####

****

1 WEEK 2 WEEKS

1 WEEK 2 WEEKS

1 WEEK 2 WEEKS

1 WEEK 2 WEEKS

BM-MNC MSC

PCN

A+C

AV1

+/m

m2

A PERI-INFARCT INFARCT

BM

-MN

CM

SCB

M-M

NC

MSC

BM

-MN

CM

SC

B

CA

V1+P

CN

A+

GFP PCNA CAV1 TOPRO3

GFP PCNA CAV1 TOPRO3

GFP PCNA CAV1 TOPRO3

GFP PCNA CAV1 TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

GFP PCNA αSMA TOPRO3

PCNA CAV1 TOPRO3

PCNA CAV1 TOPRO3

PCNA CAV1 TOPRO3

PCNA CAV1 TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

PCNA αSMA TOPRO3

1 WEEK 1 WEEK2 WEEKS 2 WEEKSPERI-INFARCT INFARCT

MYO

FIB

(αSM

A+)

PC

NA

+

PCN

A+α

SMA

+ (M

YOFI

B)/m

m2

SMC

(αSM

A+)

PC

NA

+

PCN

A+α

SMA

+ (M

YOFI

B)/m

m2

PCN

A+α

SMA

+ (S

MC

)/mm

2

PCN

A+α

SMA

+ (S

MC

)/mm

2

RESULTS: MECHANISMS OF ACTION

•Treatment with bone marrow stem cells (BM-MNC or MSC) induced a long-lasting (3 months) improvement in cardiac function. Moreover, animals injected with MSC showed an increase of tissue metabolism, which was associated with a decreased infarct size and collagen content and a higher degree of revascularization.

•The benefits observed after bone marrow stem cell transplantation were possibly due to paracrine mechanisms involved in angiogenesis and host cell proliferation and not through direct cell contribution.

CONCLUSIONS

top related